Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing

• Status: Terminated
• Trial end date: 2010-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The use of lidocaine, as an anesthetic drug, during implantation of an implantable cardioverter-defibrillator(ICD)will not result in a clinically significant alteration of the defibrillation threshold during ICD placement.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Drexel University College of Medicine
• Treatments: Lidocaine; Propofol

Criteria

Inclusion Criteria:

• Any person referred to the Hahnemann University Hospital Electrophysiology Laboratory for a clinically indicated ICD implant

Exclusion Criteria:

• Any person under the age of 18 years

• Inability to give an informed consent

• Allergy to lidocaine

• Receiving lidocaine treatment for pain or arrhythmia

• Contraindication for DFT testing

• Not consenting for DFT testing

• Receiving energy other than 10-12.5 joules as initial DFT test

• Implant of ICD on the right side

• DFT not planned to be performed during ICD implant

• Epicardial placement of ICD leads

• Use of single coil ICD lead

• Subpectoral ICD implantation

• Cephalic cutdown used for central venous access

• Require more than 3mg/kg of 1% SQ lidocaine for local anesthesia

• Pregnant women or prisoners